EU to Propose New Rules Limiting Children's Access to Social Media 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Amy Coney Barrett Faces Conservative Backlash After Key Supreme Court Rulings Against Trump 
Sara Duterte Impeachment Trial Opens, Putting 2028 Philippine Election in Focus 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
US Supreme Court Strikes Down Hawaii Gun Carry Law on Private Property 
Brazil Court Bars Flavio Bolsonaro From Visiting Jair Bolsonaro Ahead of Election 
Apple Challenges India Antitrust Probe, Says CCI Copied Rivals’ Claims in App Store Case 
US Appeals Court Limits ICE Detention Without Bond Hearings After 90 Days 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
LG Energy Solution Q2 Profit Plunges 77% Despite Revenue Growth on Weak EV Demand 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
A federal jury in California has ordered Apple to pay $634 million to Masimo after finding that features in the Apple Watch infringed on the medical-technology company’s blood-oxygen monitoring patent. The decision concludes that Apple’s workout mode and heart rate notification tools violated Masimo’s intellectual property, according to a spokesperson for the company.
Apple says it strongly disagrees with the ruling and will appeal. The tech giant noted that Masimo has pursued more than two dozen patent claims against Apple over the past six years, most of which were deemed invalid. Apple also stressed that the patent at the center of this case expired in 2022 and applies to older, traditional patient-monitoring technology.
Masimo celebrated the verdict, calling it a major step toward protecting its long-standing innovations. The lawsuit is part of a broader legal battle that has intensified tensions between the two companies. Masimo has accused Apple of poaching its employees and misappropriating its pulse oximetry technology for use in Apple Watch models.
The ongoing dispute previously contributed to a U.S. International Trade Commission (ITC) decision that temporarily blocked imports of the Apple Watch Series 9 and Ultra 2 in 2023. The ban was based on findings that Apple’s blood-oxygen technology infringed Masimo’s patents. To sidestep the import halt, Apple removed the pulse-oximetry feature from affected watches and later released an updated version approved by U.S. Customs and Border Protection.
However, the ITC announced it will reassess whether Apple’s updated models should still face restrictions. Masimo has also taken legal action against Customs over its approval decision, while Apple continues to challenge the ITC’s original import ruling in federal court.
This long-running dispute has seen mixed results on both sides. A separate trade-secret trial in California ended in a mistrial in 2023, and Apple won only $250 in a Delaware case claiming Masimo’s devices infringed two Apple design patents.
